Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec:251:196-201.e4.
doi: 10.1016/j.jpeds.2022.07.056. Epub 2022 Aug 9.

Incidence and Clinical Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 Infection After Vaccination in Children

Megan E Reyna  1 , Priya R Edward  1 , Egon A Ozer  2 , Lacy M Simons  2 , Judd F Hultquist  2 , Ramon Lorenzo-Redondo  2 , Ami B Patel  3 , Larry K Kociolek  4
Affiliations
Case Reports

Incidence and Clinical Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 Infection After Vaccination in Children

Megan E Reyna et al. J Pediatr. 2022 Dec.

Abstract

The objective of this single-center cohort study was to characterize the frequency, clinical characteristics, and molecular epidemiology of pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after vaccination. Between May 15, 2021, and January 1, 2022, 171 children experienced SARS-CoV-2 infection postvaccination, 146 (86%) following the Omicron variant predominance. Outcomes were generally mild and comparable before and after Omicron predominance.

Keywords: COVID-19; SARS-CoV-2; breakthrough; pediatric; vaccine.

PubMed Disclaimer

Figures

Figure 2
Figure 2
Days between full vaccination and positive SARS-CoV-2 test for 98 patients with a successfully sequenced SARS-CoV-2 nasopharyngeal sample. Samples are organized from longest to shortest period between being fully vaccinated (ie, day 0 is 14 days after receiving dose 2) and infection date. Among the 98 samples, 93 (94.9%) were Omicron (blue), 4 (4.1%) were Delta (yellow), and 1 (1%) was Gamma (red). For the 5 non-Omicron samples, the number of days between vaccination and a positive SARS-CoV-2 test is labeled beside the line.
Figure 1
Figure 1
Incidence of total SARS-CoV-2 infection and SARS-CoV-2 infection after vaccination at Lurie Children's during the A, pre-Omicron study period (May 15, 2021, to December 11, 2021, prior to the substantial surge in SARS-CoV-2 infection activity) and B, the complete study period (May 15, 2021, to January 1, 2022). The solid line represents the total incidence of pediatric SARS-CoV-2 infection, and the dashed line represents the total incidence of SARS-CoV-2 infection after vaccination. In B, arrows indicate date of Food and Drug Administration Emergency Use Authorization of Pfizer-BioNTech SARS-CoV-2 mRNA vaccine in children and young adults aged 0-20 years. Not shown is the initial authorization of SARS-CoV-2 vaccine in adolescents aged 16+ years on December 11, 2020.
See this image and copyright information in PMC

References

    1. Klein N.P., Stockwell M.S., Demarco M., Gaglani M., Kharbanda A.B., Irving S.A., et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years—VISION Network, 10 states, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:352–358. - PMC - PubMed
    1. Tenforde M.W., Self W.H., Gaglani M., Ginde A.A., Douin D.J., Talbot H.K., et al. Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death—United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:459–465. - PMC - PubMed
    1. Thompson M.G., Natarajan K., Irving S.A., Rowley E.A., Griggs E.P., Gaglani M., et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:139–145. - PMC - PubMed
    1. Dejnirattisai W., Huo J., Zhou D., Zahradník J., Supasa P., Liu C., et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467–484.e15. - PMC - PubMed
    1. Glatman-Freedman A., Bromberg M., Hershkovitz Y., Sefty H., Kaufman Z., Rita Dichtiar R., et al. Effectiveness of BNT162b2 vaccine booster against SARS-CoV-2 infection and breakthrough complications. Israel. Emerg Infect Dis. 2022;28:948–956. - PMC - PubMed

Publication types

Substances

Supplementary concepts